JP2021525519A5 - - Google Patents
Info
- Publication number
- JP2021525519A5 JP2021525519A5 JP2020566666A JP2020566666A JP2021525519A5 JP 2021525519 A5 JP2021525519 A5 JP 2021525519A5 JP 2020566666 A JP2020566666 A JP 2020566666A JP 2020566666 A JP2020566666 A JP 2020566666A JP 2021525519 A5 JP2021525519 A5 JP 2021525519A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- method characterized
- antigen receptor
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679348P | 2018-06-01 | 2018-06-01 | |
| US62/679,348 | 2018-06-01 | ||
| US201862753485P | 2018-10-31 | 2018-10-31 | |
| US62/753,485 | 2018-10-31 | ||
| PCT/US2019/034900 WO2019232370A1 (en) | 2018-06-01 | 2019-05-31 | Materials and methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525519A JP2021525519A (ja) | 2021-09-27 |
| JP2021525519A5 true JP2021525519A5 (cg-RX-API-DMAC7.html) | 2022-06-02 |
| JP7411578B2 JP7411578B2 (ja) | 2024-01-11 |
Family
ID=68698433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566666A Active JP7411578B2 (ja) | 2018-06-01 | 2019-05-31 | 癌を治療するための物質及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210214723A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801563B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7411578B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210020946A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112512533A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019277660A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020024601A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3101991A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2959645T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020013017A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019232370A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| CN111757744A (zh) | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| EP3849572A4 (en) * | 2018-09-10 | 2022-07-13 | Humanigen, Inc. | METHOD OF TREATMENT OF IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST |
| US12624086B2 (en) * | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113088540B (zh) * | 2020-01-08 | 2024-12-06 | 上海交通大学医学院附属瑞金医院 | 一种gm-csf敲低的t细胞及其用途 |
| AU2021347320A1 (en) * | 2020-09-24 | 2023-05-11 | The Jackson Laboratory | Humanized mouse models for assessing immune cell therapy |
| CN114934071B (zh) * | 2021-04-30 | 2023-10-17 | 四川大学华西医院 | 一种表达免疫调节因子的car载体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PL4019041T3 (pl) | 2012-07-13 | 2023-05-08 | The Trustees Of The University Of Pennsylvania | Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| EP3359650A4 (en) * | 2015-10-08 | 2019-03-20 | Innovative Cellular Therapeutics Co., Ltd. | ACTIVATION AND EXPANSION OF CELLS |
| EP3452499A2 (en) * | 2016-05-06 | 2019-03-13 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| CN107746831B (zh) * | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2019
- 2019-05-31 US US15/733,836 patent/US20210214723A1/en active Pending
- 2019-05-31 ES ES19812602T patent/ES2959645T3/es active Active
- 2019-05-31 BR BR112020024601-8A patent/BR112020024601A2/pt not_active IP Right Cessation
- 2019-05-31 MX MX2020013017A patent/MX2020013017A/es unknown
- 2019-05-31 CA CA3101991A patent/CA3101991A1/en active Pending
- 2019-05-31 EP EP19812602.1A patent/EP3801563B1/en active Active
- 2019-05-31 JP JP2020566666A patent/JP7411578B2/ja active Active
- 2019-05-31 CN CN201980046671.2A patent/CN112512533A/zh active Pending
- 2019-05-31 WO PCT/US2019/034900 patent/WO2019232370A1/en not_active Ceased
- 2019-05-31 AU AU2019277660A patent/AU2019277660A1/en not_active Abandoned
- 2019-05-31 KR KR1020207038042A patent/KR20210020946A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy | |
| EP3215605B1 (en) | Improved method for the generation of genetically modified cells | |
| JP7411578B2 (ja) | 癌を治療するための物質及び方法 | |
| FI3599251T3 (fi) | Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen | |
| JP2019523001A5 (cg-RX-API-DMAC7.html) | ||
| CN111051502A (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| JP2025023916A5 (cg-RX-API-DMAC7.html) | ||
| Bascuas et al. | Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice | |
| JP2022511735A5 (cg-RX-API-DMAC7.html) | ||
| JP2022517461A5 (cg-RX-API-DMAC7.html) | ||
| EA017613B1 (ru) | Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования | |
| Tan et al. | Interferon-γ-Inducing Factor Elicits Antitumor Immunity Association with Interferon-γ Production | |
| TW202325320A (zh) | 用於產生原代免疫細胞之方法 | |
| US11098283B2 (en) | T cells modified to overexpress c-Myb | |
| Notario et al. | CD69 targeting enhances anti-vaccinia virus immunity | |
| US20190062409A1 (en) | Use of modified hiv-1 for generating fully human antibodies | |
| CN112300997A (zh) | 通用型car-t细胞及其制备和应用 | |
| CN112262212B (zh) | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 | |
| Jeger-Madiot et al. | Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection | |
| KR20250017213A (ko) | 폴리뉴클레오티드 | |
| JP2022502066A5 (cg-RX-API-DMAC7.html) | ||
| EP4423145A1 (en) | Methods for culturing cells expressing ror1-binding protein | |
| US20200255802A1 (en) | Method for producing b cell population | |
| KR20200135760A (ko) | Ssea4에 결합하는 키메라 항원 수용체 및 이의 용도 | |
| JP2023509849A5 (cg-RX-API-DMAC7.html) |